We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

68 hedge funds and large institutions have $398M invested in KalVista Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

52% more capital invested

Capital invested by funds: $261M → $398M (+$137M)

25% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 16

19% more funds holding

Funds holding: 57 → 68 (+11)

3.33% more ownership

Funds ownership: 77.28% → 80.61% (+3.3%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

Holders
68
Holders Change
+11
Holders Change %
+19.3%
% of All Funds
1.47%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
17
Increased
20
Reduced
16
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PC
Polar Capital
United Kingdom
+$23.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$15.9M
3
Millennium Management
Millennium Management
New York
+$2.09M
4
O
OrbiMed
New York
+$1.96M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.41M

Top Sellers

Rank Fund Capital Flow
1
SHI
SV Health Investors
Massachusetts
-$15.5M
2
VMI
VHCP Management III
New York
-$6.81M
3
BI
BVF Inc
California
-$4.99M
4
VMI
VHCP Management II
New York
-$4.03M
5
BC
Broadfin Capital
New York
-$2.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$1.78M +$548K +25,267 +69%
BCM
27
Bridgeway Capital Management
Texas
$1.72M – – –
LCM
28
Laurion Capital Management
New York
$1.69M +$621K +28,670 +95%
WMSA
29
Weiss Multi-Strategy Advisers
New York
$1.54M +$282K +13,000 +32%
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$1.38M +$5.18K +239 +0.5%
WCM
31
Wedge Capital Management
North Carolina
$1.31M -$187K -8,606 -16%
Northern Trust
32
Northern Trust
Illinois
$1.17M +$3.73K +172 +0.4%
Goldman Sachs
33
Goldman Sachs
New York
$1.08M +$819K +37,790 New
Wells Fargo
34
Wells Fargo
California
$990K +$1.91K +88 +0.3%
Neuberger Berman Group
35
Neuberger Berman Group
New York
$959K +$726K +33,500 New
Barclays
36
Barclays
United Kingdom
$930K -$657K -30,289 -48%
Marshall Wace
37
Marshall Wace
United Kingdom
$843K +$638K +29,452 New
TEE
38
Tibra Equities Europe
United Kingdom
$727K +$551K +25,401 New
EI
39
EAM Investors
California
$682K -$392K -18,066 -43%
ECM
40
ExodusPoint Capital Management
New York
$666K +$504K +23,253 New
DCM
41
DAFNA Capital Management
California
$665K +$65K +3,000 +15%
Deutsche Bank
42
Deutsche Bank
Germany
$508K +$382K +17,618 +10,425%
SAM
43
Sectoral Asset Management
Quebec, Canada
$502K – – –
AG
44
Algert Global
California
$475K -$59.6K -2,750 -14%
Citigroup
45
Citigroup
New York
$350K +$265K +12,238 New
SSA
46
Schonfeld Strategic Advisors
New York
$315K +$238K +11,000 New
BCM
47
BlueCrest Capital Management
Jersey
$304K +$230K +10,620 New
Man Group
48
Man Group
United Kingdom
$268K +$203K +9,381 New
State Street
49
State Street
Massachusetts
$245K +$186K +8,575 New
Morgan Stanley
50
Morgan Stanley
New York
$214K +$144K +6,636 +781%
1
2
3

KALV Hedge Fund Activity: Q1 2019 in Review

68 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2019, worth a combined $398M — up 52% from $261M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new KALV positions and 6 closed out — a net gain of 11 holders — while 20 added to existing stakes and 16 trimmed.

The largest buyer was Polar Capital, adding an estimated $23.2M. The largest seller was SV Health Investors, cutting an estimated $15.5M.

  • 68 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2019, up from 57 in Q4 2018.
  • Funds reported $398M of KalVista Pharmaceuticals stock for Q1 2019, up 52% quarter-over-quarter.
  • 17 funds opened new KalVista Pharmaceuticals positions in Q1 2019 and 6 closed out, a net change of +11 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2019 was Polar Capital, an estimated $23.2M added.
  • The largest KalVista Pharmaceuticals seller in Q1 2019 was SV Health Investors, an estimated $15.5M sold.

Based on aggregated 13F filings for Q1 2019.